Maryland is currently home to 2668 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Baltimore, Bethesda, Rockville and Annapolis. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Imaging the Pathogenesis of Cerebral Small Vessel Disease
NCT05703386
Recruiting
Cerebral small vessel disease (CSVD) can lead to vascular cognitive impairment and dementia (VCID). The hallmark of CSVD is the appearance and progression of white matter hyperintensities (WMH) on MRI. The goal of this study it to recruit and follow individuals at risk for WMH progression and use serial MRI scanning to gain insights into the pathogenesis of CSVD.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: Kennedy Krieger Institute, Baltimore, Maryland
Conditions: Ischemic Stroke, Hypertension, Hyperlipidemias, Diabetes
Register for Updates
MyAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home
NCT05204888
Recruiting
Parallel-group, prospective, randomized, controlled phase III trial of home High flow Nasal Therapy (HFNT) via myAirvo 3 plus usual COPD medical care vs. usual COPD medical care, for at least 1 year and up to two years in 642 GOLD Grade D, Stages II-IV patients with moderate to very severe COPD at risk for moderate and severe exacerbations with a prior history of severe exacerbation requiring hospitalization within the past 6 weeks.
Gender:
ALL
Ages:
30 years and above
Trial Updated:
02/05/2025
Locations: University of Maryland - Baltimore, Baltimore, Maryland
Conditions: COPD
Register for Updates
Cerebellar Stimulation for Aphasia Rehabilitation
NCT05093673
Recruiting
The optimal site of neuromodulation for post-stroke aphasia has yet to be established. This study will investigate whether multiple sessions of cerebellar transcranial direct current stimulation (tDCS) boosts language therapy in helping people recover from aphasia as well as predict who is likely to respond to cerebellar tDCS.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
02/05/2025
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Stroke
Register for Updates
Music and Brain Stimulation for Upper Extremity Performance in Patients With Corticobasal Syndrome
NCT05073471
Recruiting
This study is designed to investigate how musical patterns (e.g., patterned sensory enhancement, PSE) and non-invasive brain stimulation (e.g., transcranial direct current stimulation, tDCS) are effective to improve functional upper extremity performances in patients with corticobasal syndrome (CBS). 20 individuals with CBS will be randomly assigned to either PSE group (n= 10) or PSE+tDCS (n=10) group. Both interventions are 30 minutes long, twice a week for three weeks (a total of 6 sessions).... Read More
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
02/05/2025
Locations: Johns Hopkins School of Medicine, Baltimore, Maryland
Conditions: Corticobasal Syndrome, Upper Extremity Dysfunction
Register for Updates
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
NCT04045665
Recruiting
The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery. All patients with a qualifying POAF event, who decline randomization, will be offered the option of enrollment in a parallel registry that captures their ba... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: University of Maryland, Baltimore, Maryland
Conditions: Atrial Fibrillation, Stroke, Bleeding
Register for Updates
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
NCT03465592
Recruiting
This research is being done to find out if an investigational drug, Nivolumab, can be safely administered after a "half-matched" (haplo) bone marrow transplant (BMT), and if the investigational drug will help to prevent or delay relapse or progression of sarcomas. In this study investigators will also be trying to learn more about how the investigational drug changes blood and/or tumors. Participants are eligible for this trial if they have recently undergone a "half-matched" (haplo) bone marrow... Read More
Gender:
ALL
Ages:
Between 12 months and 40 years
Trial Updated:
02/05/2025
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Sarcoma, Solid Tumor, Adult, Solid Tumor, Childhood
Register for Updates
The Role of IL5 in Epithelial Cell Integrity
NCT05895929
Recruiting
The goal of this laboratory study is the examine the effect of mepolizumab drug on the health and function of the cells lining the human nasal airways in vitro cell culture derived from patients with chronic rhinosinusitis with nasal polyposis. The main questions the study aims to study are: 1. To see what mepolizumab does to suppress inflammation of the human cells. 2. To see what mepolizumab does to maintain barrier integrity of epithelial cells
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
02/04/2025
Locations: Johns Hopkins Bayview Medical Center, Baltimore, Maryland
Conditions: Chronic Rhinosinusitis With Nasal Polyps, Chronic Rhinosinusitis (Diagnosis)
Register for Updates
Biodistribution and Pharmacokinetics of Pretomanid in Tuberculosis Patients Using 18F-Pretomanid PET
NCT05609552
Recruiting
This is an observational study that will examine the pretomanid pharmacokinetics (PK) in tuberculosis (TB) patients. Dynamic 18F-pretomanid PET/CT will be performed after intravenous injection of 18F-pretomanid to determine multi-compartment, noninvasive determination of pretomanid PK in TB patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: Johns Hopkins Medical Institutions, Baltimore, Maryland
Conditions: Tuberculosis
Register for Updates
APrevent-VOIS-Implant-002 - a Two-Part, Open-Label, Non-Randomized Multicenter Study
NCT05119842
Recruiting
This is a prospective, 2-part, multi-center, open-label, non-randomized clinical trial to assess safety and effectiveness of APrevent® VOIS Implants for the treatment of patients with Unilateral Vocal Fold Paralysis (UVFP). In total 30 evaluable patients are planned to be enrolled.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/04/2025
Locations: Greater Baltimore Medical Center, Baltimore, Maryland
Conditions: Paralysis, Unilateral, Vocal Cord
Register for Updates
ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study
NCT04620239
Recruiting
This is a phase 3, open label, single arm study of padeliporfin in the treatment of Upper Tract Urothelial Carcinoma (UTUC). The ENLIGHTED study will recruit patients with low-grade non-invasive upper tract urothelial carcinoma in either the kidney or the ureter. Patients will be treated with padeliporfin VTP in two phases: an Induction Treatment Phase and a Maintenance Treatment Phase and will be followed up for up to an additional 48 months in the long term (non intervention) follow up phase w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: The Johns Hopkins Hospital, The Sidney Kimmel Cancer Center, Baltimore, Maryland
Conditions: Transitional Cell Cancer of Renal Pelvis and Ureter
Register for Updates
Safety for Home Administration of Microdose Psilocybin Use
NCT06450210
Recruiting
The goal of this laboratory study is to establish whether and which microdoses of psilocybin are safe to administer at home to healthy participants. Eligible participants will be given ascending doses of psilocybin trihydrate and a single, interspersed, randomized placebo on separate days in double-blind fashion. The participants will be asked to complete questionnaires and undergo safety assessments.
Gender:
ALL
Ages:
Between 21 years and 60 years
Trial Updated:
02/03/2025
Locations: 5510 Nathan Shock Drive, Baltimore, Maryland
Conditions: Psychedelic Experiences
Register for Updates
A Study of Selinexor Monotherapy in Subjects with JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
NCT05980806
Recruiting
The main purpose of this study with corresponding optional expansion is to evaluate the efficacy of selinexor in JAKi-naïve participants with myelofibrosis (MF) and moderate thrombocytopenia based on spleen volume reduction (SVR). Additional efficacy and safety parameters will also be assessed during the study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Maryland Oncology Hematology - Independent of SCRI/ US Oncology, Columbia, Maryland
Conditions: Myelofibrosis, Moderate Thrombocytopenia
Register for Updates